乳がん治療薬市場：薬剤クラス別、治療法別、地域別、2026～2032年

乳がん治療薬市場の評価　2026～2032年

世界の乳がん罹患率の上昇により、新たな治療法のニーズが高まっています。診断技術の進歩により早期診断が可能になり、その結果、治療手段を求める患者が増加しています。さらに、乳がんに対する意識の高まりと頻繁な検査の重要性が、診断症例の増加に寄与しています。標的治療薬と免疫療法の出現は治療技術を変革し、患者により効果的で個別化された選択肢を与えます。

さらに、製薬企業による研究開発への多額の投資は、薬剤製剤の技術革新を刺激し、新たな治療法の市場投入につながり、2026年から2032年までのCAGRは約8.30%で成長すると予想されます。

乳がん治療薬市場定義/概要

乳がん治療薬には、化学療法、標的療法、ホルモン療法、免疫療法など、乳がんのさまざまな治療法が含まれます。これらの治療法は、がん細胞を死滅させ、再発を予防し、患者の生存率を高めることを目的としています。治療法は、早期発見・治療から進行した疾患管理まで、乳がんのあらゆる段階に適用され、個々の患者の特徴や腫瘍生物学に適応しています。現在の研究は、より効果的で毒性の少ない治療法の開発、個別化医療技術の向上、遺伝子治療やナノメディシンなどの新技術の導入を目指しており、乳がん治療の将来は楽観視できます。乳がんに対する認識が高まるにつれ、患者の予後やQOLを向上させる新薬が登場し、乳がん治療の様相を大きく変えると予想されます。

遺伝的素因の有病率の増加は乳がん治療薬市場を牽引するか？

乳がんに対する遺伝性素因の頻度が増加していることが、乳がん治療業界の大きな原動力となりつつあります。知識が増え、遺伝子検査がより広く利用できるようになるにつれ、遺伝性危険因子を見つける人が増え、早期介入や専門的な治療オプションが可能になります。国立がん研究所によると、乳がん発症の推定510％は遺伝性で、親から子へと受け継がれる欠陥遺伝子によって引き起こされます。2024年3月、Journal of Clinical Oncology誌に掲載された重要な調査において、2019年から2023年の間に、BRCA1およびBRCA2変異の遺伝子検査を受ける女性の数が67％増加したことが判明しました。検査の増加は早期発見と対策につながり、予防策や標的治療への需要を高めています。

2023年5月、アストラゼネカは、BRCA変異乳がんの治療に使用されるPARP阻害剤リンパーザの売上が前年比28％増となったことを報告しました。同様に、ミリアド・ジェネティクス社は2024年1月、BRCA遺伝子変異のある患者を特定するBRACAnalysis CDx検査の需要が前年から35％増加したと発表しました。規制面では、米国食品医薬品局（FDA）が2023年にBRCA変異乳がんに対する2つの新規標的治療を承認し、遺伝性リスクを持つ患者の治療選択肢を広げました。さらに2023年9月、米国立衛生研究所は、特に恵まれない地域での遺伝子検査とカウンセリング・サービスへのアクセスを強化するための5,000万米ドルのプロジェクトを発表しました。これらの進展は、2024年までに米国の女性で297,790例の浸潤性乳がんが新たに確認されるという米国がん協会の予測とともに、乳がん治療における遺伝的リスクの治療の必要性が高まっていることを強調しています。

高度化学療法のコスト増は乳がん治療薬市場の成長を阻害するか？

高度な化学療法にかかる費用の増加は、多くの患者にとって重要な治療法へのアクセスを制限することにより、乳がん治療薬市場の成長を阻害すると予想されます。ヘルスケアシステムが予算制限や処方箋価格の上昇に直面する中、患者は、特に保険適用が限られている地域では、自己負担額を支払うのに苦労する可能性があります。このような費用の障壁は、治療開始の遅れ、処方された薬剤の服薬率の低下、ひいては健康状態の悪化を引き起こし、市場全体の成長に深刻な影響を及ぼす可能性があります。

さらに、コストの上昇により、医療提供者や支払者がより厳しい償還基準を導入する可能性があり、革新的な新治療法が市場で受け入れられることが難しくなります。その結果、製薬会社は先進的な化学療法の上市やマーケティングが困難になり、研究開発投資が減少する可能性があります。その結果、革新的な治療が妨げられ、生命を救う可能性のある治療法の上市が妨げられ、市場の拡大が制限され、患者やヘルスケアプロバイダーが利用できる選択肢の数が減少する可能性があります。

目次

第1章 世界の乳がん治療薬市場の導入

• 市場イントロダクション
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の乳がん治療薬市場見通し

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 乳がん治療薬の世界市場：薬剤クラス別

• 概要
• HER2阻害薬
• 有糸分裂阻害薬

第6章 乳がん治療薬の世界市場：治療法別

• 概要
• 化学療法
• 放射線療法

第7章 乳がん治療薬の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の乳がん治療薬市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• AstraZeneca plc
• Eisai Co. Ltd.
• Eli Lilly and Company
• Roche Diagnostics
• Novartis AG
• Pfizer Inc.
• Celgene
• Sanofi S.A.
• Teva Pharmaceutical
• GlaxoSmithKline plc.

第10章 付録

• 関連調査

Breast Cancer Therapeutics Market Valuation - 2026-2032

The rising global incidence of breast cancer is fuelling need for new therapeutic alternatives. Advances in diagnostic technologies enable earlier diagnosis, resulting in a greater number of patients seeking therapeutic measures. Furthermore, the increased awareness of breast cancer and the significance of frequent tests contribute to the increase in diagnosed cases. The emergence of targeted medicines and immunotherapies has transformed treatment techniques, giving patients more effective and individualized options is surpassing USD 30.52 Billion in 2024 and reaching USD 54.52 Billion by 2032.

Furthermore, pharmaceutical corporations' significant investments in research and development stimulate innovation in medication formulations, leading to the launch of new treatments in the market is expected to grow at a CAGR of about 8.30% from 2026 to 2032.

Breast Cancer Therapeutics Market: Definition/ Overview

Breast cancer medicines include a variety of treatments for breast cancer, such as chemotherapy, targeted therapy, hormone therapy, and immunotherapy. These therapies aim to kill cancer cells, prevent recurrence, and increase patient survival rates. Applications cover all stages of breast cancer, from early detection and treatment to advanced disease management, and are adapted to individual patient features and tumour biology. The future of breast cancer therapies seems optimistic, with current research aimed at producing more effective and less toxic treatment alternatives, improving personalized medicine techniques, and incorporating emerging technologies such as gene therapy and Nanomedicines. As awareness of the condition improves, novel medicines that boost patient outcomes and quality of life are expected to emerge, significantly changing the face of breast cancer treatment.

Will Rising Prevalence of Genetic Predisposition Drive the Breast Cancer Therapeutics Market?

The increasing frequency of hereditary predisposition to breast cancer is becoming a major driver of the breast cancer treatments industry. As knowledge rises and genetic testing becomes more widely available, an increasing number of people are finding their hereditary risk factors, allowing for earlier interventions and specialized treatment options. According to the National Cancer Institute, an estimated 510% of breast cancer occurrences are hereditary, caused by faulty genes passed down from parent to kid. In March 2024, in a significant study published in the Journal of Clinical Oncology, researchers discovered that between 2019 and 2023, the number of women getting genetic testing for BRCA1 and BRCA2 mutations grew by 67%. Increased testing has led to earlier detection and action, raising demand for preventive measures and targeted therapies.

In May 2023, AstraZeneca reported a 28% year-over-year growth in sales of Lynparza, a PARP inhibitor used to treat BRCA-mutated breast cancer. Similarly, Myriad Genetics said in January 2024 that demand for its BRACAnalysis CDx test, which identifies patients with BRCA mutations, had increased by 35% from the previous year. On the regulatory front, the United States Food and Drug Administration (FDA) approved two novel targeted treatments for BRCA-mutated breast cancers in 2023, broadening therapy choices for patients with hereditary risk. Furthermore, in September 2023, the National Institutes of Health announced a USD 50 Million project to enhance access to genetic testing and counseling services, particularly in underprivileged areas. These advancements, together with the American Cancer Society's forecast that around 297,790 new cases of invasive breast cancer will be identified in women in the United States by 2024, emphasizing the growing necessity of treating genetic risk in breast cancer therapies.

Will Increasing Cost of Advanced Chemotherapies Hinder the Growth of the Breast Cancer Therapeutics Market?

The rising expense of sophisticated chemotherapies is expected to stymie the growth of the breast cancer therapeutics market by limiting access to these critical treatments for many patients. As healthcare systems face budget restrictions and growing prescription prices, patients may struggle to afford out-of-pocket expenses, particularly in areas with limited insurance coverage. This cost barrier can cause delays in treatment commencement, less adherence to prescribed medications, and eventually inferior health outcomes, severely influencing total market growth.

Furthermore, rising costs may cause healthcare providers and payers to implement more stringent reimbursement criteria, making it difficult for new, innovative therapies to acquire market acceptability. As a result, pharmaceutical companies may have difficulties in launching and marketing advanced chemotherapies, perhaps resulting to a reduction in R&D investments. This could hinder innovation and prevent the launch of potentially life-saving treatments, thus restricting market expansion and lowering the number of options available to patients and healthcare providers.

Category-Wise Acumens

Will Rising Demand of HER2 Inhibitors Drive the Breast Cancer Therapeutics Market?

The rising demand for HER2 inhibitors is expected to considerably boost the breast cancer treatments market, owing to the increasing prevalence of HER2-positive breast cancer and the effectiveness of these targeted therapies. HER2 inhibitors, including trastuzumab (Herceptin) and newer medicines like neratinib and tucatinib, have shown significant success in improving patient outcomes and overall survival rates. For instance, in May 2023, the United States Food and Drug Administration (FDA) approved trastuzumab deruxtecan (Enhertu) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have had two or more previous anti-HER2-based regimens. This clearance demonstrates the ongoing innovation and growth of treatment choices in this field, which fuels demand and increases competition among pharmaceutical companies.

In June 2023, Daiichi Sankyo announced good results from clinical studies for DS-8201, a new HER2-targeted medication, indicating a potential breakthrough in treatment for HER2-positive breast cancer patients. Government initiatives and financing for breast cancer research are also improving the landscape, as evidenced by the National Cancer Institute's grant program inaugurated in March 2023 to assist the development of new HER2-targeted medicines. This convergence of demand, innovation, and regulatory backing is expected to drive the breast cancer treatments market ahead, particularly in the HER2 inhibitor category.

The mitotic inhibitors market is also expanding rapidly, driven by rising demand for combination therapies and the need for effective treatments in triple-negative breast cancer (TNBC). Paclitaxel and docetaxel are important agents in the treatment of several forms of breast cancer, and their use in combination with other therapies is becoming more common. As research advances and new mitotic inhibitors are created, this industry is likely to experience significant expansion, particularly as healthcare providers strive to diversify therapy choices for patients who may not respond to conventional medicines.

Will Increasing Usage of Chemotherapy Fuel the Breast Cancer Therapeutics Market?

Chemotherapy is likely to propel the breast cancer treatments market as it remains a key treatment for various stages of the disease. Chemotherapy is especially important for individuals with aggressive forms of breast cancer, such as triple-negative breast cancer (TNBC), where treatment options are frequently limited. Recent advancements in chemotherapy regimens, such as the incorporation of novel drugs that reduce adverse effects while increasing efficacy, are adding to its enduring appeal. For instance, in July 2023, the FDA granted rapid clearance for sacituzumab govitecan (Trodelvy) as a therapy for patients with unresectable locally advanced or metastatic TNBC who had received at least two previous regimens. This approval demonstrates the continuous commitment to improve chemotherapy choices and increasing its role in breast cancer treatment.

Furthermore, in April 2023, government programs, such as the National Cancer Institute's funding program, which began, prioritize support for research into novel chemotherapeutic techniques. These findings suggest that the growing reliance on chemotherapy, together with ongoing innovations and supporting government frameworks, will likely fuel expansion in the breast cancer therapies market.

Radiation therapy is also expanding rapidly, especially as part of a multidisciplinary approach to breast cancer treatment. Radiation technology advancements, including as intensity-modulated radiation therapy (IMRT) and partial breast irradiation, have enhanced treatment precision and reduced side effects, resulting in increased patient and doctor acceptability. Furthermore, the tendency toward de-escalation of therapies in early-stage breast cancer, where radiation therapy might serve as a less invasive option after surgery, contributes to its growing significance.

Country/Region-wise

Will Rising Widespread Access to Targeted Therapies and Immunotherapies in North America Drive the Breast Cancer Therapeutics Market?

The increasing availability of targeted treatments and immunotherapies is expected to significantly impact the breast cancer therapeutics market in North America. As healthcare practitioners adopt more novel treatment choices, patients benefit from better outcomes and fewer side effects than traditional medications. According to recent statistics, the use of targeted therapies such as HER2 inhibitors and CDK4/6 inhibitors has increased patient survival rates, with studies demonstrating a 33% reduction in the risk of disease progression in hormone receptor-positive breast cancer patients who receive these therapies. In August 2023, the FDA expanded the indication for palbociclib (Ibrance), a CDK4/6 inhibitor, to cover first-line treatment with aromatase inhibitors, demonstrating the rising acceptance and integration of targeted medicines in clinical practice.

Furthermore, government measures are promoting greater access to these treatments. For instance, the Biden administration's focus on healthcare reforms has resulted in greater Medicare coverage for immunotherapies, making it simpler for patients to get treatments like pembrolizumab (Keytruda), which has been demonstrated to be effective in triple-negative breast cancer. According to in September 2023 study by the American Society of Clinical Oncology (ASCO), around 65% of breast cancer patients now have access to targeted treatments and immunotherapies, up from 50% two years before. This increased trend in access, together with continuous research and development efforts by firms like Genentech and Merck, is likely to further fuel the growth of the breast cancer treatments market in North America, offering patients with more effective treatment alternatives.

Will Rising Awareness of Breast Cancer in Asia Pacific Propel the Breast Cancer Therapeutics Market?

Rising breast cancer awareness in the Asia Pacific region is expected to considerably drive the breast cancer treatments market as more people appreciate the value of early detection and treatment. Educational initiatives and community outreach projects have helped raise awareness of breast cancer risk factors and screening methods. In October 2023, According to a World Health Organization (WHO) report published, the incidence of breast cancer in Asia has climbed by nearly 20% over the last decade, emphasizing the critical need for better therapies. This increased awareness has resulted in higher screening rates and subsequent diagnoses, driving demand for a wide range of treatment choices, including targeted medicines and chemotherapy.

Furthermore, government initiatives are playing an important role in increasing access to breast cancer therapies in the region. For example, in September 2023, the Indian government announced a new national breast cancer control program aimed at improving screening and treatment facilities across the country, hence increasing access to sophisticated therapies. Similarly, Roche and the Chinese government formed a collaboration in August 2023 to provide access to HER2-targeted treatments in underprivileged areas. According to research from the Asia Pacific Oncology Society, as awareness grows, the market for breast cancer therapies is expected to rise at a compound annual growth rate (CAGR) of 9.5% until 2028. This convergence of increased awareness and supported government efforts is projected to considerably enhance breast cancer therapeutics market in the Asia Pacific area, resulting in better patient outcomes and survival rates.

Competitive Landscape

The competitive landscape of the breast cancer therapeutics market is marked by intense innovation, with a strong focus on targeted therapies, immunotherapies, and personalized medicine. Numerous mid-sized pharmaceutical and biotech companies are actively developing novel therapies aimed at improving efficacy and reducing side effects compared to traditional chemotherapy. Companies are leveraging advancements in precision medicine, particularly in hormone receptor-positive (HR+), HER2-positive, and triple-negative breast cancer (TNBC), to offer more effective treatments based on the molecular profile of patients.

Some of the prominent players operating in the breast cancer therapeutics market include:

AstraZeneca plc

Eisai Co. Ltd.

Eli Lilly and Company

Roche Diagnostics

Novartis AG

Pfizer, Inc.

Celgene

Sanofi S.A.

Teva Pharmaceutical

GlaxoSmithKline plc.

Amgen

Merck

Latest Developments

In August 2023, Merck announced that the FDA had increased its approval of pembrolizumab (Keytruda) for the treatment of triple-negative breast cancer in conjunction with chemotherapy for certain patients. This approach emphasizes immunotherapy's growing importance in treating aggressive breast cancer forms.

In September 2023, The Indian government launches a countrywide breast cancer control program to improve screening, diagnosis, and treatment accessibility. This program, which is funded by collaborations with pharmaceutical companies, is projected to enhance outcomes for breast cancer patients nationwide.

In September 2023, Novartis reported encouraging findings from a study using ribociclib (Kisqali) in combination with endocrine therapy for premenopausal women with hormone receptor-positive breast cancer. The results showed improved outcomes, confirming Kisqali as a key player in the breast cancer therapies scene.

Breast Cancer Therapeutics Market, By Category

• Drug Class:
• HER2 Inhibitors
• Mitotic Inhibitors
• Therapy:
• Chemotherapy
• Radiation Therapy
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BREAST CANCER THERAPEUTICS MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BREAST CANCER THERAPEUTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY DRUG CLASS

• 5.1 Overview
• 5.2 HER2 Inhibitors
• 5.3 Mitotic Inhibitors

6 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY THERAPY

• 6.1 Overview
• 6.2 Chemotherapy
• 6.3 Radiation Therapy

7 GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL BREAST CANCER THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 AstraZeneca plc
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Eisai Co. Ltd.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Eli Lilly and Company
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Roche Diagnostics
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Novartis AG
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Pfizer Inc.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Celgene
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Sanofi S.A.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Teva Pharmaceutical
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 GlaxoSmithKline plc.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research